
|Videos|December 16, 2017
Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer
Author(s)Eileen O'Reilly, MD
Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.
Advertisement
Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early-stage pancreatic cancer.
The major change for patients with early-stage pancreatic cancer is the combination of cytotoxic chemotherapy in the adjuvant setting. Data from ESPAC-4 study demonstrated that the addition of capecitabine to gemcitabine had an improvement in overall survival with low toxicity.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5



































